KAMIL ALI-JACKSON

Corporate Board Profile

Tech Score: 0/100

RIGEL PHARMACEUTICALS INC

Filing Date	Source Excerpt
2022-04-05	Kamil Ali-Jackson, age 63, joined us as a director in December 2021. Ms. Ali-Jackson brings nearly four decades of biopharmaceutical industry experience to Rigel, including expertise in negotiating licensing, joint venture, and M&A transactions to drive strategic growth. ... Ms. Ali-Jackson currently serves on the board of directors, audit committee, compensation committee, and is the chair of the nominating and corporate governance committee of PDS Biotechnology Corporation, ... Ms. Ali-Jackson was selected to serve as a member of the Board in part due to her broad experience in the areas of acquisitions, licensing, legal, and corporate governance as well as her experience as an executive officer, legal counsel, and co-founder in the biopharmaceutical industry.

Filing Date

Source Excerpt

2022-04-05

Kamil Ali-Jackson, age 63, joined us as a director in December 2021. Ms. Ali-Jackson brings nearly four decades of biopharmaceutical industry experience to Rigel, including expertise in negotiating licensing, joint venture, and M&A transactions to drive strategic growth. ... Ms. Ali-Jackson currently serves on the board of directors, audit committee, compensation committee, and is the chair of the nominating and corporate governance committee of PDS Biotechnology Corporation, ... Ms. Ali-Jackson was selected to serve as a member of the Board in part due to her broad experience in the areas of acquisitions, licensing, legal, and corporate governance as well as her experience as an executive officer, legal counsel, and co-founder in the biopharmaceutical industry.

Data sourced from SEC filings. Last updated: 2026-03-05